Ascendis Pharma
Founded in Copenhagen, Denmark in 2007, Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we utilize our innovative TransCon™ technology platform to create new and potentially best-in-class therapies.
Today, we’re advancing programs in Endocrinology Rare Disease, Oncology, and Ophthalmology. We currently have five product candidates in clinical development: three in Endocrinology Rare Disease and two in Oncology. In addition, Ascendis recently announced new pre-clinical programs in Ophthalmology.
We are a dynamic, growing biopharma company with headquarters in Copenhagen and additional offices and research facilities in Germany (Heidelberg, Munich, and Berlin) and the United States (Palo Alto, California, and Princeton, New Jersey).
Is Ascendis Pharma hiring?
Yes — Ascendis Pharma has 45 open jobs on JobsRadar right now, across 20 departments and 23 locations. 20 of them were opened in the last 30 days. 19 of them disclose pay, with a median of $195,000 a year and most offers between $165,000 and $227,500. The board was last refreshed on September 8, 2026 at 01:34 UTC.
Frequently asked questions
- Is Ascendis Pharma hiring?
- Yes. Ascendis Pharma has 45 open jobs on JobsRadar as of September 8, 2026. 20 of them were opened in the last 30 days.
- What roles is Ascendis Pharma hiring for?
- Ascendis Pharma is hiring for roles in Global IT, Global Regulatory Affairs & Patient Safety, Endocrine and Rare Disease Medical Sciences and Legal, Compliance, Risk & IPR.
- What does Ascendis Pharma pay?
- Across the 19 Ascendis Pharma jobs that disclose pay, the median is $195,000 a year, and most offers fall between $165,000 and $227,500.
- How current are these listings?
- Every listing comes straight from the employer’s own careers system and is re-checked three times a day. This page was last updated on September 8, 2026 at 01:34 UTC.